Observations from the OMERACT Drug Safety Summit, May 2008

Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their giv...

Full description

Saved in:
Bibliographic Details
Published in:Journal of rheumatology 2009-09, Vol.36 (9), p.2110-2113
Main Authors: SIMON, Lee S, VIBEKE STRAND, C, BOERS, Maarten, BROOKS, Peter M, HENRY, David, TUGWELL, Peter S
Format: Article
Language:English
Subjects:
Antirheumatic Agents - adverse effects
Antirheumatic Agents - therapeutic use
Biological and medical sciences
Diseases of the osteoarticular system
Drug Discovery
Drug-Related Side Effects and Adverse Reactions
Humans
Medical sciences
Rheumatic Diseases - drug therapy
Risk Assessment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to mounting concern about determination of benefit and risk in the context of product development and clinical practice the OMERACT Executive identified the need to bring together a variety of specialists to define risk. At the Drug Safety Summit held at OMERACT 9, specialists spoke on their given topics and the group considered risk in the context of formally posed questions.
ISSN:0315-162X
1499-2752
DOI:10.3899/jrheum.090590